CN103191268A - Traditional Chinese medicinal composition for treating lung cancer - Google Patents
Traditional Chinese medicinal composition for treating lung cancer Download PDFInfo
- Publication number
- CN103191268A CN103191268A CN2013101550860A CN201310155086A CN103191268A CN 103191268 A CN103191268 A CN 103191268A CN 2013101550860 A CN2013101550860 A CN 2013101550860A CN 201310155086 A CN201310155086 A CN 201310155086A CN 103191268 A CN103191268 A CN 103191268A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicinal composition for treating lung cancer, and belongs to the technical field of traditional Chinese medicines. Against the problem that current medicaments cannot be used for effectively treating lung cancer, the invention provides the traditional Chinese medicinal composition consisting of pseudo-ginseng, lucid ganoderma, tripterygium wilfordii, ginseng, rhizoma calami, pangolin, common andrographis herb, angelica and liquorice. The traditional Chinese medicinal composition is good in anti-cancer activity in the field of treating lung cancer and other solid tumors, and can be used as a medicament for treating lung cancer.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the therapeutic combination of pulmonary carcinoma, particularly a kind of Chinese medicine composition and application thereof for the treatment of pulmonary carcinoma.
Background technology
At present, cancer is that current serious influences human health, threatens one of principal disease of human life.Cancer constitutes world today's All Countries three big causes of death with cardiovascular and cerebrovascular disease and contingency.Therefore, World Health Organization (WHO) and hygiene department of national governments all classify capture cancer as a top priority as.Treat method for cancer in the world and mainly contain three kinds, the one, adopt surgical excision, removal lesion tissue prevents the cancerous cell diffusion; The 2nd, adopt chemotherapy or radiotherapy, with kill cancer cell; The 3rd, heal with medicine.The method of employing excision has increased patient's misery, hinders its vigour, and expense is huge.With the method for chemotherapy or radiotherapy, in kill cancer cell, also injure erythrocyte and leukocyte, patient suffers untold misery.
Nonsmall-cell lung cancer is modal pulmonary carcinoma histological type, accounts for about 85% of pulmonary carcinoma.Nonsmall-cell lung cancer comprises several types such as squamous cell cancer, adenocarcinoma and large cell carcinoma again, and the growth of cancer cells of non-small cell carcinoma is slow, and grade malignancy is low relatively, and it is later that diffusion transfer takes place.The treatment of nonsmall-cell lung cancer mainly comprises surgical operation therapy, radiotherapy, chemotherapy, Chinese medicine and is the novel method for the treatment of of representative with molecular targeted treatment clinically, but nonsmall-cell lung cancer is poor to the sensitivity of chemotherapy, radiotherapy, and seeking effective Therapeutic Method is the problem that solution is needed in current nonsmall-cell lung cancer treatment badly.
Chinese medicine tumor historical of long standing and well established, and as an importance of modern combined therapy of tumour, more and more receive publicity in recent years.People seek single pharmaceutically active ingredient from traditional Chinese herbal medicine or compound recipe is treated cancer tool challenge.
Summary of the invention
Still do not have very effectively Drug therapy at present pulmonary carcinoma, first purpose of the present invention is to provide a kind of Chinese medicine composition for the treatment of pulmonary carcinoma, and this Chinese medicine composition has good active anticancer aspect pulmonary carcinoma.Chinese medicine composition of the present invention is made by following parts by weight of Chinese traditional medicine material: 10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.Above-mentioned Chinese medicine composition can be prepared as follows and obtain: at first, according to the components by weight percent meter, get each component of following weight portion: 10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae;
Secondly, add the 5-10 water doubly of medical material gross weight, soaked 60-90 minute, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1-1.3, and this relative density is the testing result under 60 degrees centigrade, adds ethanol and is 75-95%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, namely.
Sweet, the little hardship of Radix Notoginseng meridian distribution of property and flavor, tepor.Return liver, stomach warp.Function cures mainly removing stasis to stop bleeding, the promoting blood circulation and detumescence analgesic therapy.Cure mainly the various blood disorders that go out, tumbling down congestive edema, obstruction of qi in the chest and cardialgia.Modern pharmacology confirms that its main pharmacological has two: (1) antitumor action: arasaponin Rd can make the tumor cell 92% of cultivation be suppressed, and Rd also has obvious inhibitory action to the oncocyte of cultivating.Saponin Rhl can suppress the growth of murine melanoma (B16), make cancerous cell again induction be reversed into non-cancerous cell.The Radix Notoginseng decoct has inhibitory action to JYC26 in vivo; Polysaccharide body in the Radix Notoginseng can obviously suppress murine sarcoma-180 in vivo; Radix Notoginseng also has the antiphagin activity.(2) to Immune Effects: Radix Notoginseng total arasaponins can improve macrophage phagocytosis of mice and humoral immune function.To the influential composition of immunologic function, mainly be Radix Notoginseng total arasaponins and Radix Notoginseng polysaccharide in the Radix Notoginseng.In addition, the pseudo-ginseng water immersion can be shortened the rabbit clotting time, and platelet count is increased and anastalsis is arranged; Rat experiment arthritis there is tangible preventive and therapeutic action; Nervus centralis there are excitement, inhibitory action, also have analgesic activity; Can obviously increase coronary artery blood flow, reduce myocardial oxygen consumption; Also have effects such as antiinflammatory, adrenal cortex reinforcing function.
Ganoderma is China's Chinese medicine material, contains several physiological active substances, has effects such as strengthening the body resistance, enhancing body immunity, and wherein triterpenoid compound is topmost effective ingredient.Active component triterpenoid compound scalable human body 100 several genes in the Ganoderma; Find more than 20 kind of triterpene when modern medicine uses fingerprint pattern technology that Ganoderma class medicine is studied, wherein 8 kinds is new cancer-resisting substance.Squama Manis is good at walking to scurry, and property specially row is loose, energy promoting blood circulation to remove blood stasis, current meridians; Radix Angelicae Sinensis, its property is sweet, hot, warm, returns liver, the heart, spleen channel, enriching blood and invigorate blood circulation, is the first medicine of Chinese medicine hematonic, contains this lactone of algae, n-butene phthalein lactone, benzene penta phenol phosphorus carboxylic acid, angelicone, fragrant Jing Jie phenol, 2,4-dihydro acid phthalic anhydride etc., other contains choline and 13 seed amino acids, polysaccharide sucrose, vitamin B12, category-A material and folic acid, nicotinic acid, cupreol etc., and in-vitro screening has the effect of the tumor cell of inhibition, and suppression ratio is about 50%～70%.
Rhizoma Acori Calami is warm in nature, acrid in the mouth, hardship, GUIXIN, spleen, Liver Channel.Function cures mainly has one's ideas straightened out, and reduces phlegm stomach invigorating, refreshment.Be used for diseases such as epilepsy, expectorant febrile convulsion, breast abdominal distention are vexed, chronic bronchitis.Modern plants learn to confirm to contain α-, beta-Asarone, cis-Methylisoeugenol, methyleugenol, Rhizoma Acori Graminei enediol (cal-amendiol), Rhizoma Acori Graminei helicene ketone (acorenone), acolamone (shyobunone), acorone (acorone), the big bull ketone of Rhizoma Acori Graminei (acoragermacrone), acorone (acolamone) isoreactivity composition, use it for tumors such as treatment gastric cancer, pulmonary carcinoma, good anticancer function is arranged.
Herba Andrographis is acanthaceous plant Herba Andrographis (Andrographis paniculata(Burm.f.) Nees) herb or leaf, main product is in provinces such as Guangdong, Fujian, also introduce a fine variety on ground such as Central China, North China, northwest.Have heat-clearing and toxic substances removing, antiinflammatory, reducing swelling and alleviating pain effect.Cure mainly bacillary dysentery, urinary tract infection, acute tonsillitis, enteritis, pharyngolaryngitis, pneumonia and influenza etc., external can be treated furuncle toxic swelling, trauma infection contamination etc.
Radix Tripterygii Wilfordii is the root of Celastraceae plant Radix Tripterygii Wilfordii, cries Caulis Fibraureae, beeswax rattan, cabbageworm medicine, red medicine, water Folium illicii Lanceolati again, main product in Fujian, ground such as Zhejiang, Anhui, Henan.Bitter in the mouth, suffering, cool in nature, big poison.Return liver, kidney channel.Effect expelling wind and removing dampness, removing obstruction in the collateral to relieve pain, reducing swelling and alleviating pain, detoxifcation parasite killing.Be used for damp and hot tuberosity, the long-pending poison of carcinoma, treat lepra reaction, rheumatoid arthritis etc. with it clinically, pharmacological research shows that also it has effects such as antitumor, antiinflammatory.
Radix Notoginseng, Ganoderma and Radix Tripterygii Wilfordii have the effect of dispersing swelling and dissipating binds, detoxicating and fighting cancer; Radix Ginseng, Rhizoma Acori Calami, Squama Manis blood circulation promoting and blood stasis dispelling, removing mass collateral dredging; Reuse Radix Angelicae Sinensis and Herba Andrographis, set upright with QI invigorating, beneficial blood is enriched blood, and makes eliminating evil just the wound, helps just with eliminating evil; The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, and play the effect that detoxicating and fighting cancer, hard masses softening and resolving, blood circulation promoting and blood stasis dispelling, QI invigorating are set upright altogether.
The present invention is by investigating Chinese medicine composition antagonism S180 sarcoma cell mice-transplanted tumor of the present invention experiment, find that Chinese medicine composition provided by the invention has the curative effect of obvious inhibition S180 tumor, this shows that Chinese medicine composition antagonism mice S180 tumor of the present invention has obtained unforeseeable curative effect of medication.Especially the Chinese medicine composition best results of the preferred following components by weight percent of the present invention:
10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.Chinese medicine composition of the present invention can be prepared into the treatment that suitable pharmaceutical preparation is used for tumor patient, is preferably mixture, capsule and tablet.
In addition, the present invention is by the effect of research Chinese medicine composition of the present invention to inhibition lung cancer Lewis solid tumor aspect, experimental result finds that Chinese medicine composition of the present invention is suppressing to have good therapeutic effect aspect the lung cancer Lewis solid tumor, can be used as anti-lung cancer drugs and uses.Based on this, the invention provides a kind of medical usage of above-mentioned Chinese medicine composition, namely described Chinese medicine composition is preparing the purposes for the treatment of in the cancer drug, and wherein said cancer is preferably pulmonary carcinoma.
In a word, the present invention compared with prior art has good active anticancer, and can be used as the cancer therapy drug use; And Chinese medicine composition preparation of the present invention is simple, and nontoxic substantially, raw material is easy to get, and is suitable for popular use, has good application prospects.
The specific embodiment
Below further describe the present invention by the specific embodiment, but the present invention is not limited only to following examples.Within the scope of the invention or in not breaking away from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they all are regarded as comprising within the scope of the present invention.
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 60 minutes, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 75%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, packing, flowing steam sterilization 35min namely gets mixture.
Embodiment 2 Chinese medicine composition tablets of the present invention
Prescription: 10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 90 minutes, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.3, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 80%(v/v to containing the alcohol amount), left standstill 24 hours, and got supernatant, reclaim ethanol to concentrating, vacuum drying, granulation, tabletting are namely.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 80 minutes, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 95%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, vacuum drying is granulated, and is namely encapsulated.
The 1 Chinese medicine composition antagonism S180 sarcoma cell mice-transplanted tumor of the present invention experiment of test example
1, is subjected to reagent thing and laboratory animal
Kunming mouse 18～25 g, male and female half and half, totally 50.Murine sarcoma S180 cell, ftorafur, Chinese medicine composition of the present invention (preparation technology is with embodiment 1-3).
, S180 sarcoma cell mice-transplanted tumor model foundation
The S180 cell culture in RPMI-1640,37 ℃, 5%CO
2Following conventional the cultivation gone down to posterity once in average per 2 days, and being prepared into density with normal saline during to exponential phase is 3.0 * 10
7/ mL single cell suspension, in under the aseptic condition in mouse peritoneal (about 5 mices, the male and female dual-purpose), inoculates back about 10 days and see the obvious enlargement of mouse peritoneal, take off neck this moment and put to death mice, put into the beaker that fills 75% ethanol and soak 2～3 min, the mice of sterilizing is put in the superclean bench, picks up abdomen middle part skin with tweezers, cut off skin in hypogastric region with operating scissors and expose abdominal part, pass abdominal muscles with asepsis injector and extract ascites, it is standby to put into aseptic reagent bottle.
The ascites of above-mentioned extraction is counted with trypan blue, adopted the transplanting liquid of tumor cell＞95% to dilute with normal saline, adjust cell number to 2 * 10
7～6 * 10
7Individual/moL.
One people is mice fixedly, and another people's left hand has been pinched the right front axillary region skin of mice, and is along gauffer that the insertion of 1 mL syringe needle is subcutaneous, every mouse inoculation 0.4mL cell suspension.
, grouping and administration
Weighing next day in inoculation back, selects the close and healthy mice of body weight to be divided into 4 groups at random, and 10 every group, male and female half and half, every the record of weighing.Behind inoculated tumour cell 24 h, gavage administration (administration classification and administration concentration are as shown in table 1).Every 0.3 mL, every day 1 time, continuous 14 d.
Table 1 is respectively organized dosage regimen
4, testing index:
24 h on an empty stomach after the last administration take off neck and put to death mice, weigh, and strip the tumor piece and weigh.Calculate tumour inhibiting rate (%)=(the average tumor of the average tumor weight-experimental group of negative control group is heavy)/average tumor of negative control group heavy * 100%
,Get tumor and carry out pathological examination.
, the result
Through the pathological section laboratory observation, that excises is organized as tumor tissues, organizes atypia less.Result of the test shows, the first, and Chinese medicine composition 1-3 group of the present invention all has significant curative effect of medication to S180; The second, the tumour inhibiting rate that Chinese medicine composition of the present invention is 1 group is higher than 3 groups of 2 groups of Chinese medicine compositions of the present invention and Chinese medicine compositions of the present invention far away up to 40.4-43.7%.This shows that the effect of Chinese medicine composition antagonism mice S180 tumor of the present invention is remarkable, 2 groups of best results of Chinese medicine composition especially of the present invention.
The contrast of table 2 administration forebody-afterbody quality and tumour inhibiting rate
Test example 2 Chinese medicine compositions of the present invention influence transplantability Mice Bearing Lewis Lung Cancer tumour inhibiting rate
1 research purpose
Study Chinese medicine composition of the present invention to the solid tumor inhibitory action of the mice of oxter plantation lung cancer Lewis tumor strain.
Test sample and reference substance
2.1 test sample: Chinese medicine composition of the present invention, cold preservation, airtight preservation
2.2 reference substance: the multiple recovery oral liquid (Yicun Pharmaceutical Co., Ltd., Jiangxi) of gold, room temperature, airtight keeping in Dark Place
2.3 test sample: Chinese medicine composition of the present invention (participating in the embodiment of the invention 1)
The grouping of 3 laboratory animals and recognition methods
60 of SPF level KM mices, the quality certification number: 8122, half and half, 4 age in week of male and female, 22～26 g.
3.1 group technology: divide into groups according to the completely random group technology; Male and female are divided into groups respectively.
3.2 recognition methods: adopt 3% picric acid staining, labelling is as shown in table 4 between group.
Labelling between table 3 mice group
3.3 animal feeding environmental condition
Conventional environment, 20～25 ℃, temperature difference per day≤3 ℃; Humidity is 40%～70%; Animal illumination: 15～20 lx; Work illumination: more than 150 lx; Before test is carried out and after the off-test room is carried out thorough cleaning-sterilizing.Cleaning after whole ends of job every day, sterilization.
3.4 feedstuff, bedding and padding and drinking-water
SPF Mus material, and irradiated feed (lot number: 10063023), the conventional raising, free choice feeding is freely drunk water;
4 test methods
4.1 dosage design: the design of administration group dosage sees Table 5.
Postvaccinal mice is divided into 6 groups at random, 10 every group, male and female half and half.
Table 4 mice dosage and mode
4.2 test method:
Mice lung cancer Lewis tumor strain cell culture in RPMI-1640,37 ℃, 5%CO
2Following conventional the cultivation gone down to posterity once in average per two days, and being prepared into density with normal saline during to exponential phase is 3.0 * 10
7Individual/the ml single cell suspension, under aseptic condition, be injected in the mouse peritoneal, inoculate back 7 days and see the obvious enlargement of mouse peritoneal, at this moment, take off neck and put to death, put into the beaker that fills 75% ethanol and soaked 2～3 minutes, the mice after the sterilization is put into superclean bench, expose abdominal part, it is standby to put into aseptic reagent bottle with asepsis injector extraction ascites.Above-mentioned ascites is counted with trypan blue, with the normal saline dilution, adjusted cell number to 1.0 * 10
7Individual/ml, be inoculated in the right oxter of mice, every 0.4ml.
1 time (every morning administration) pressed table 6 gastric infusion every day in beginning administration in the 4th day after the animal inoculation tumor; Model group is irritated the normal saline of stomach equivalent.Successive administration 10 days.
Index detects
5.1 body weight
Detection frequency: reach before the grouping and dissect preceding weighing animal body weight on an empty stomach.
Instrument and equipment: ACS-3A-a type electronic scale, Shanghai Dahua Electronic Scale Factory
5.2 tumor quality
Detect frequency: administration finishes test after 10 days, sacrificed by exsanguination is cutd open inspection.
The histoorgan of weigh: oxter tumor
Cut open detecting method: lumbar injection 2% pentobarbital sodium (0.2 mlkg
-1) anesthesia, after the abdomen cardinal vein is got blood and finished, cut off the ventral aorta sacrificed by exsanguination, carry out conventional oxter then and get tumor.
Instrument and equipment: BS224S type electronic balance, Beijing Sai Duolisi instrument system company limited
ACS-6A type electronic price computing scale, Shanghai Dahua Electronic Scale Factory
6 data statistics processing methods
Test data with
Expression adopts SPSS 11.5 statistical softwares to carry out date processing.
Experimental result
Experimental result shows (experimental result sees Table 5):
Compare with model group, the tumour inhibiting rate of Chinese medicine composition low dose group of the present invention and high dose group obviously improves, and has significant difference.
Above experimental result further illustrates, and Chinese medicine composition of the present invention is suppressing to have good therapeutic effect aspect the lung cancer Lewis solid tumor, can be used as anti-lung cancer drugs and uses.
The influence of table 5 Chinese medicine composition of the present invention and tumour inhibiting rate heavy to the mouse lung carcinoma (
)
Attention:
▲Compare p＜0.05 with the model group group.
Claims (4)
1. Chinese medicine composition for the treatment of pulmonary carcinoma is characterized in that being made by following parts by weight of Chinese traditional medicine material: 10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
2. treat the preparation method of the Chinese medicine composition of pulmonary carcinoma according to claim 1, it is characterized in that comprising the steps:
At first, get following Chinese crude drug according to weight portion: 10 parts in 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae;
Secondly, add the 5-10 water doubly of medical material gross weight, soaked 60-90 minute, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1-1.3, and this relative density is the testing result under 60 degrees centigrade, adds ethanol and is 75-95%v/v to containing the alcohol amount, left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, namely.
3. the Chinese medicine composition for the treatment of pulmonary carcinoma as claimed in claim 1, it is characterized in that: described Chinese medicine composition is mixture, tablet or capsule.
4. the Chinese medicine composition of the arbitrary described treatment pulmonary carcinoma of claim 1-3 is preparing the purposes for the treatment of in the cancer drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310155086.0A CN103191268B (en) | 2013-04-29 | 2013-04-29 | Traditional Chinese medicinal composition for treating lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310155086.0A CN103191268B (en) | 2013-04-29 | 2013-04-29 | Traditional Chinese medicinal composition for treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191268A true CN103191268A (en) | 2013-07-10 |
| CN103191268B CN103191268B (en) | 2014-07-09 |
Family
ID=48714202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310155086.0A Active CN103191268B (en) | 2013-04-29 | 2013-04-29 | Traditional Chinese medicinal composition for treating lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191268B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768399A (en) * | 2014-02-28 | 2014-05-07 | 郭成业 | Traditional Chinese medicinal composition for treating lung cancer and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961466A (en) * | 2010-10-09 | 2011-02-02 | 何龙 | Snake venom capsule for treating cancer |
-
2013
- 2013-04-29 CN CN201310155086.0A patent/CN103191268B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961466A (en) * | 2010-10-09 | 2011-02-02 | 何龙 | Snake venom capsule for treating cancer |
Non-Patent Citations (3)
| Title |
|---|
| 张家骝等: "《肺癌的中西医结合治疗》", 《云南中医中药杂志》 * |
| 王羲明: "《论中医药防治恶性肿瘤的优势》", 《山东中医杂志》 * |
| 纪钧等: "《中医治癌经验精华》", 31 May 1999, 江苏科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768399A (en) * | 2014-02-28 | 2014-05-07 | 郭成业 | Traditional Chinese medicinal composition for treating lung cancer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191268B (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100363022C (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN102845745A (en) | Dendrobium officinale health-care product | |
| CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
| WO2013071727A1 (en) | Anti-tumor traditional chinese medical composition | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN101347543A (en) | Chinese medicine compound and preparation method thereof | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN104056242A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and preparation method thereof | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN103768570B (en) | A kind of Chinese medicine composition for the treatment of acute cholecystitis and preparation method thereof | |
| CN106309758A (en) | Pharmaceutical composition with efficacy of resisting gastrointestinal cancer | |
| CN101011543A (en) | Antineoplastic medicine composition | |
| CN102716382A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
| CN114159533B (en) | Traditional Chinese medicine composition for treating multiple drug-resistant bacterial infection and application thereof | |
| CN104096065A (en) | Traditional Chinese medicine composition for treating non-small cell lung cancer | |
| CN100551404C (en) | Medicament for inducing diuresis to alleviate edema preparation of compositions and detection method and purposes | |
| CN102949681A (en) | Composition for preventing or treating colds, and its preparation method | |
| CN101564409B (en) | Application of traditional Chinese indian lettuce in preparation of diabetes drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BINZHOU MEDICAL UNIVERSITY HOSPITAL Free format text: FORMER OWNER: CUI XINMING Effective date: 20140610 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gao Lixia Inventor after: Ning Fangling Inventor after: Shang Xiqin Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XUEJIAN TO: GAO LIXIA NING FANGLING SHANG XIQIN Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 256600 BINZHOU, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140610 Address after: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Applicant after: Binzhou Medical University Hospital Address before: 266200, No. seven, 179 village, Wenquan Town, Jimo, Shandong, Qingdao Applicant before: Cui Xinming |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CUI XINMING Free format text: FORMER OWNER: BINZHOU MEDICAL UNIVERSITY HOSPITAL Effective date: 20140718 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 256600 BINZHOU, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140718 Address after: 266200 No. seven village, 179 hot springs town, Shandong, Jimo Patentee after: Cui Xinming Address before: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Patentee before: Binzhou Medical University Hospital |
|
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CUI XINMING Effective date: 20140826 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140826 Address after: 226200 Qidong chemical industry park, Jiangsu, Nantong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 266200 No. seven village, 179 hot springs town, Shandong, Jimo Patentee before: Cui Xinming |